These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 77316)

  • 21. Myoclonus and seizures in a patient with parkinsonism: induction by levodopa and its confirmation on SEPs.
    Yoshida K; Moriwaka F; Matsuura T; Hamada T; Tashiro K
    Jpn J Psychiatry Neurol; 1993 Sep; 47(3):621-5. PubMed ID: 8301877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Bromocriptine versus levodopa in the early treatment of Parkinson's disease. 1st results after 2 years].
    Montastruc JL; Rascol O; Rascol A
    Therapie; 1988; 43(6):461-3. PubMed ID: 3227512
    [No Abstract]   [Full Text] [Related]  

  • 23. Dilemma in the treatment of Parkinson's disease with L-dopa.
    Kuno S
    Eur Neurol; 1994; 34 Suppl 3():17-9. PubMed ID: 7821330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of Parkinson's disease with 8-alpha-amino-ergoline, CU 32-085.
    Schneider E; Hubener K; Fischer PA
    Neurology; 1983 Apr; 33(4):468-72. PubMed ID: 6682193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the effects of bromocriptine and levodopa in Parkinson's disease.
    Godwin-Austen RB; Smith NJ
    J Neurol Neurosurg Psychiatry; 1977 May; 40(5):479-82. PubMed ID: 330825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Combined treatment of the early stages of Parkinson's syndrome with bromocriptine and levodopa. The results of a multicenter study].
    Fischer PA; Przuntek H; Majer M; Welzel D
    Dtsch Med Wochenschr; 1984 Aug; 109(34):1279-83. PubMed ID: 6381019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.
    BMJ; 1993 Aug; 307(6902):469-72. PubMed ID: 8400928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical assessment of therapeutic results of Ergolactyn (bromocriptine) in Parkinson's disease].
    Kuran W; Kulczycki J
    Neurol Neurochir Pol; 1993; 27(4):507-13. PubMed ID: 8247238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine].
    Montastruc JL; Schmitt L; Bagheri H
    Rev Neurol (Paris); 2003 Apr; 159(4):441-3. PubMed ID: 12773874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson's disease.
    Todman DH; Oliver WA; Edwards RL
    Clin Exp Neurol; 1990; 27():79-82. PubMed ID: 2129961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peculiarities of L: -DOPA treatment of Parkinson's disease.
    Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
    Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A double-blind study of bromocriptine and L-dopa in de novo Parkinson's disease. Short-term results.
    Riopelle RJ; Gawel MJ; Libman I; King DB; McLean DR; Paulseth R; Raphy B; Bouchard S
    Eur Neurol; 1988; 28 Suppl 1():11-4. PubMed ID: 3288477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Long-term results of treatment of Parkinson's disease with bromocriptine and domperidone (author's transl)].
    Agid Y; Quinn N; Lhermitte F
    Rev Neurol (Paris); 1981; 137(1):49-51. PubMed ID: 7232966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
    Svenningsson P; Rosenblad C; Af Edholm Arvidsson K; Wictorin K; Keywood C; Shankar B; Lowe DA; Björklund A; Widner H
    Brain; 2015 Apr; 138(Pt 4):963-73. PubMed ID: 25669730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease].
    Kannari K; Kurahashi K; Tomiyama M; Maeda T; Arai A; Baba M; Suda T; Matsunaga M
    No To Shinkei; 2002 Feb; 54(2):133-7. PubMed ID: 11889759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The treatment of Parkinson disease using the combination bromocriptine and levodopa].
    Dufresne JJ
    Rev Med Suisse Romande; 1990 Jun; 110(6):559-64. PubMed ID: 2367793
    [No Abstract]   [Full Text] [Related]  

  • 38. Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa.
    Parkes JD; Debono AG; Marsden CD
    J Neurol Neurosurg Psychiatry; 1976 Nov; 39(11):1101-8. PubMed ID: 1036999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Comparison of bromocriptine and levodopa as first line treatment of Parkinson's disease: results of a 3-year prospective randomized study].
    Montastruc JL; Rascol O; Rascol A
    Rev Neurol (Paris); 1990; 146(2):144-7. PubMed ID: 2181588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding.
    Bédard PJ; Di Paolo T; Falardeau P; Boucher R
    Brain Res; 1986 Aug; 379(2):294-9. PubMed ID: 3488796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.